SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
March 18, 2024 03:00 ET
|
Senisca Ltd
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and...
SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman
November 14, 2023 02:00 ET
|
Senisca Ltd
SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman Highly experienced biotech veteran to support SENISCA’s rapid development of its senotherapeutic...
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer
November 02, 2023 03:00 ET
|
Senisca Ltd
SENISCA appoints Dr. Sarah Cole as Chief Executive Officer Exeter, UK — 02 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and...
SENISCA shortlisted for 2022/2023 Nature Spinoff prize
May 25, 2023 03:00 ET
|
Senisca Ltd
SENISCA shortlisted for 2022/2023 Nature Spinoff prize Exeter, UK – 25 May 2023: SENISCA, a UK biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the...
SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF).
April 20, 2023 02:00 ET
|
Senisca Ltd
Exeter, UK – 20 April 2023: SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the diseases of ageing, today announces that it has been...